Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. more
Time Frame | TLSI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.32% | -3.35% | -2.97% |
1-Month Return | -12.62% | -3.49% | -0.66% |
3-Month Return | -21.57% | -12.6% | 2.71% |
6-Month Return | -36.62% | -6.91% | 7.21% |
1-Year Return | -54.55% | 1.19% | 23.04% |
3-Year Return | -63.75% | -0.21% | 28.43% |
5-Year Return | -65.78% | 33.09% | 82.88% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | 8.40M | 12.40M | 18.51M | [{"date":"2021-12-31","value":45.38,"profit":true},{"date":"2022-12-31","value":66.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Cost of Revenue | 1.19M | 2.26M | 2.60M | [{"date":"2021-12-31","value":45.8,"profit":true},{"date":"2022-12-31","value":86.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Gross Profit | 7.21M | 10.14M | 15.91M | [{"date":"2021-12-31","value":45.32,"profit":true},{"date":"2022-12-31","value":63.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Gross Margin | 85.80% | 81.79% | 85.93% | [{"date":"2021-12-31","value":99.85,"profit":true},{"date":"2022-12-31","value":95.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Expenses | 31.24M | 46.58M | 70.06M | [{"date":"2021-12-31","value":44.59,"profit":true},{"date":"2022-12-31","value":66.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | (24.03M) | (36.44M) | (54.15M) | [{"date":"2021-12-31","value":-2403200000,"profit":false},{"date":"2022-12-31","value":-3643900000,"profit":false},{"date":"2023-12-31","value":-5415000000,"profit":false}] | ||
Total Non-Operating Income/Expense | (6.57M) | (10.56M) | (4.46M) | [{"date":"2021-12-31","value":-657100000,"profit":false},{"date":"2022-12-31","value":-1056000000,"profit":false},{"date":"2023-12-31","value":-446400000,"profit":false}] | ||
Pre-Tax Income | (28.84M) | (47.18M) | (59.03M) | [{"date":"2021-12-31","value":-2884200000,"profit":false},{"date":"2022-12-31","value":-4717800000,"profit":false},{"date":"2023-12-31","value":-5902900000,"profit":false}] | ||
Income Taxes | 3.00K | 9.00K | 9.00K | [{"date":"2021-12-31","value":33.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Income After Taxes | (28.84M) | (47.19M) | (59.04M) | [{"date":"2021-12-31","value":-2884500000,"profit":false},{"date":"2022-12-31","value":-4718700000,"profit":false},{"date":"2023-12-31","value":-5903800000,"profit":false}] | ||
Income From Continuous Operations | (28.84M) | (47.19M) | (59.04M) | [{"date":"2021-12-31","value":-2884500000,"profit":false},{"date":"2022-12-31","value":-4718700000,"profit":false},{"date":"2023-12-31","value":-5903800000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | (28.84M) | (47.19M) | (59.04M) | [{"date":"2021-12-31","value":-2884500000,"profit":false},{"date":"2022-12-31","value":-4718700000,"profit":false},{"date":"2023-12-31","value":-5903800000,"profit":false}] | ||
EPS (Diluted) | 0.15 | 0.18 | (1.87) | [{"date":"2021-12-31","value":83.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1039.06,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
TLSI | |
---|---|
Cash Ratio | 1.14 |
Current Ratio | 2.40 |
Quick Ratio | 2.00 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TLSI | |
---|---|
ROA (LTM) | -133.15% |
ROE (LTM) | -496.21% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TLSI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.74 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TLSI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 4.64 |
P/B | 30.29 |
Price/FCF | NM |
EV/R | 4.72 |
EV/Ebitda | NM |
TriSalus Life Sciences Inc. (TLSI) share price today is $3.576
Yes, Indians can buy shares of TriSalus Life Sciences Inc. (TLSI) on Vested. To buy TriSalus Life Sciences Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TLSI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of TriSalus Life Sciences Inc. (TLSI) via the Vested app. You can start investing in TriSalus Life Sciences Inc. (TLSI) with a minimum investment of $1.
You can invest in shares of TriSalus Life Sciences Inc. (TLSI) via Vested in three simple steps:
The 52-week high price of TriSalus Life Sciences Inc. (TLSI) is $10.42. The 52-week low price of TriSalus Life Sciences Inc. (TLSI) is $3.5.
The price-to-earnings (P/E) ratio of TriSalus Life Sciences Inc. (TLSI) is
The price-to-book (P/B) ratio of TriSalus Life Sciences Inc. (TLSI) is 30.29
The dividend yield of TriSalus Life Sciences Inc. (TLSI) is 0.00%
The market capitalization of TriSalus Life Sciences Inc. (TLSI) is $114.65M
The stock symbol (or ticker) of TriSalus Life Sciences Inc. is TLSI